Patent reform in the US: What's at stake for pharmaceutical innovation?

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 5, 2010, Pages 603-608

  Yancey, Amy ^a   Stewart Jr , Charles Neal ^b  

^a University of Tennessee Libraries   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Intellectual property; Patent reform; Patents; Pharmaceutical industry; Research and development; Therapeutic patents; University research; US patent law

Indexed keywords

DRUG INDUSTRY; FEE; INVESTMENT; LAW; MONEY; PATENT; REVIEW; UNITED STATES; UNIVERSITY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; TIME FACTORS; UNITED STATES;

EID: 77951555554     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003709775     Document Type: Review

References (35)

1. US. Const. art. I § 8
2. Merges RP, Duffy JF. Patent law and policy: cases and materials. 3rd edition. LexisNexus, Mathew Bender; 2002. p. 2-3
3. The Patent Act (1793), 35 USC § 102-102
4. Scherer FM. The political economy of patent policy reform in the United States. J Telecomm High Tech L 2009;20:167-216
5. Bayh-Dole Act (1980), 35 USC § 200-212.
6. Diamond v Chakrabarty (1980), 447 US. 303.
7. The United States Patent and Trademark Office (USPTO). Available from: www. uspto.gov/patents/stats/appbacklog.jsp. [Last accessed 21 December 2009]
8. Yancey A, Stewart CN. Patents: are university researchers at risk? Nat Biotechnol 2007;25:1225-1228
9. Williams EE. Patent Reform: the pharmaceutical industry prescription for post-grant opposition and remedies. J Pat Trademark Off Soc'y 2008;90:354-377
10. Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science 1998;280:698-701
11. Lemley MA. Ignoring Patents. Mich St L Rev 2008;20:19-34
12. Corbett RM. Harmonization of US and foreign patent law and HR 2795: the Patent Reform Act of 2005, 2006. Fla J Int'l L 2006;18:717-734
13. Jackson CM. The war on drugs: how KSR v Teleflex and Merck v. Integra continue the erosion of pharmaceutical patent protection. Cap UL Rev 2007;36:1029-1064
14. Furrow ME. Pharmaceutical patent life-cycle management after KSR v Teleflex. Food Drug LJ 2008;63:275-320
15. Brekke K, Straume O. Pharmaceutical patents: incentives for research and development or marketing? South Econ J 2009;76(2):351-374
16. Teitelbaum R, Cohen M. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Nat Biotechnol 2007;25:1105-1106 (Pubitemid 47538105)
17. Albainy-Jenei S. Patent Reform 2009: still too many competing interests. Patent Baristas. Available from: www.patentbaristas.com/archives/2009/ 03/24/patent-reform-2009-still-toomany- competing-interests/ March 24, 2009. [Last accessed 17 October 2009]
18. PhRMA Statement on the Patent Reform Act of 2009. Pharmaceutical Research and Manufacturers of America Statement, 2009. Available from: www.phrma.org/news-room/ press-releases/phrma-statement-on- patent-reform-act- of-2009/. [Last accessed 10 October 2009]
19. BIO Urges Senate Committee to Improve Patent Reform Legislation, Raises Concerns about Broader Economic Impact of Certain Provisions. Biotechonology Industry Organization press release, 2009. Available from: http://bio.org/news/ pressreleases/ newsitem.asp?id=2009-0310-01. [Last accessed 4 February 2010]
20. Strictland D. Patent Reform Battle Pits Biotech against High-Tech. Genet Eng Biotechnol News. Available from: www.genengnews.com/news/ bnitem-print.aspx?name=50688785. [Last accessed 19 November 2009]
21. Borras S, Kahin B. Patent reform in Europe and the US. Sci Public Policy 2009;36(8):631-640
22. PhRMA Statement of Patent Reform Agreement. Pharmaceutical Research and Manufacturers of America Statement, 2010. Available from: http://www.phrma.org/ news/news/ phrma-statement-patent- reform-agreement. [Last accessed 27 March 2010]
23. BIO Thanks Senate Judiciary Leaders for Advancing Patent Reform. Biotechnology Industry Organization press release, 2010. Available from: http://www.bio.org/news/pressreleases/ newsitem.asp?id=2010-0304-03. [Last accessed 27 March 2010]
24. US. Senate Bill 515
25. Opderbeck DW. 89 B.U. L. Rev. 127 (2009) Patent Damages Reform and the Shape of Patent Law, DW 89 B.U. L. Rev. 2009;127:127-188
26. University views on S. 515, the Patent Reform Act of 2009. Statement from the Association of American Universities, American Council on Education, Association of American Medical Colleges, Association of Public and Land-grant Universities, and Council on Governmental Relations. 2009. Available from www.aau.edu/policy/patent-reform. aspx?id=9604 [Last accessed 23 November 2009]
27. Boettiger S, Bennett A. Bayh-Dole: if we knew then what we know now. Nat Biotechnol 2006;24:320-323
28. Crouch D. Patent Reform 2009: Damages. Available from: www.patentlyo.com/patent/2009/03/ patent-reform-2009-damages.html. [Last accessed 2 March 2010]
29. Hutson S. Pharma 'patent trolls remain mostly the stuff of myth. Nat Med 2009;15:1240 doi:10.1038/ nm1109-1240a
30. Goldman D. Recession's latest victim: U.S. innovation. Available from money. cnn.com/2009/12/11/news/economy/ patent-filings/. [Last accessed 14 December 2009]
31. Eisenberg RS. One sixe fits all, after tailoring. Science 2009;325:1625
32. Data collected from the USPTO. Available from: www.uspto.gov/web/ offices/ac/ido/oeip/taf/us-stat.htm. [Last accessed 21 December 2009]
33. Bartz D. Tentative US patent reform pact reached-Sen. Leahy. Available from: www.reuters.com/ article/idUSN2511331720100225. [Last accessed 2 March 2010]
34. Data collected from the USPTO. Available from: www.uspto.gov/patents/ stats/appbacklog.jsp. [Last accessed 21 December 2009]
35. Senators Hatch, Leahy introduce Patent Reform Act of 2009. United States Senator Orrin G. Hatch press release, 2009. Available from: hatch.senate.gov/ public/index.cfm?FuseAction=Press Releases.Detail&PressRelease-id= ce28c6f0-1b78-be3e-e028-418ea18126e5 &Month=3&Year=2009. [Last accessed 7 October 2009]